




Searching News Database: dementia
HSMN NewsFeed - 11 Oct 2023
Labcorp Launches New Test to Accelerate Path to Diagnosis of Alzheimer's Disease
Labcorp Launches New Test to Accelerate Path to Diagnosis of Alzheimer's Disease
HSMN NewsFeed - 27 Jul 2022
Eisai Announces Key Executive Appointment for Alzheimer's Disease Leadership
Eisai Announces Key Executive Appointment for Alzheimer's Disease Leadership
HSMN NewsFeed - 20 Apr 2022
AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio
AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio
HSMN NewsFeed - 8 Dec 2021
KeifeRx Completes $6 Million Series A Financing and Enhances Board of Directors
KeifeRx Completes $6 Million Series A Financing and Enhances Board of Directors
HSMN NewsFeed - 5 Jul 2021
Transine Therapeutics Appoints Industry Veteran Jan Thirkettle Ph.D. as CEO
Transine Therapeutics Appoints Industry Veteran Jan Thirkettle Ph.D. as CEO
HSMN NewsFeed - 24 Jun 2021
Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease
Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease
HSMN NewsFeed - 24 Aug 2020
Yumanity Therapeutics and Proteostasis Therapeutics Announce Merger Agreement
Yumanity Therapeutics and Proteostasis Therapeutics Announce Merger Agreement
HSMN NewsFeed - 2 Mar 2020
ANI Pharmaceuticals Announces FDA Approval of Memantine Hydrochloride Extended-Release Capsules
ANI Pharmaceuticals Announces FDA Approval of Memantine Hydrochloride Extended-Release Capsules
HSMN NewsFeed - 3 Feb 2020
Eisai Inc. Expands Leadership Team in the US with the Appointment of Two Key Leaders
Eisai Inc. Expands Leadership Team in the US with the Appointment of Two Key Leaders
HSMN NewsFeed - 30 Oct 2019
Biogen and Alkermes Announce FDA Approval of VUMERITY(TM) (diroximel fumarate) for Multiple Sclerosis
Biogen and Alkermes Announce FDA Approval of VUMERITY(TM) (diroximel fumarate) for Multiple Sclerosis
HSMN NewsFeed - 26 Aug 2019
Priya Chaturvedi, Ph.D., Appointed Vice President of Global Clinical Quality Assurance at Eisai Inc.
Priya Chaturvedi, Ph.D., Appointed Vice President of Global Clinical Quality Assurance at Eisai Inc.
HSMN NewsFeed - 4 Jun 2019
Patrick Coyle Appointed Vice President and Chief Financial Officer of Eisai Inc.
Patrick Coyle Appointed Vice President and Chief Financial Officer of Eisai Inc.
HSMN NewsFeed - 11 Dec 2018
Avanir Pharmaceuticals Announces Termination of License Agreement with Optinose for ONZETRA(R) Xsail(R)
Avanir Pharmaceuticals Announces Termination of License Agreement with Optinose for ONZETRA(R) Xsail(R)
HSMN NewsFeed - 1 Nov 2018
Chris Cargill Appointed Executive Vice President and Chief Financial Officer of Sosei
Chris Cargill Appointed Executive Vice President and Chief Financial Officer of Sosei
HSMN NewsFeed - 9 Jul 2018
Mylan Adds to Central Nervous System Portfolio With Launch of Generic Exelon(R) Patch
Mylan Adds to Central Nervous System Portfolio With Launch of Generic Exelon(R) Patch
HSMN NewsFeed - 12 Jun 2018
Update on Phase 3 Clinical Trials of Lanabecestat for Alzheimer's Disease
Update on Phase 3 Clinical Trials of Lanabecestat for Alzheimer's Disease
HSMN NewsFeed - 6 Apr 2018
Impax Launches a Generic Version of Estrace(R) Cream (estradiol vaginal cream, USP, 0.01%)
Impax Launches a Generic Version of Estrace(R) Cream (estradiol vaginal cream, USP, 0.01%)
HSMN NewsFeed - 29 Dec 2017
Mylan Adds to U.S. Women's Healthcare Portfolio With FDA Approval of First Generic for Estrace(R) Cream
Mylan Adds to U.S. Women's Healthcare Portfolio With FDA Approval of First Generic for Estrace(R) Cream
HSMN NewsFeed - 12 Jul 2017
E-Scape Bio Series A Extension Brings Total Round to $63 Million to Fund Neurodegenerative Disease Pipeline
E-Scape Bio Series A Extension Brings Total Round to $63 Million to Fund Neurodegenerative Disease Pipeline
HSMN NewsFeed - 27 Jun 2017
Mitoconix Bio Raises $20 Million in Series A Funding to Develop Neurodegenerative Disease Therapies
Mitoconix Bio Raises $20 Million in Series A Funding to Develop Neurodegenerative Disease Therapies
HSMN NewsFeed - 31 Aug 2016
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC(R) Patent Litigation
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC(R) Patent Litigation
HSMN NewsFeed - 21 Jun 2016
Neurotrope Appoints Paula T. Trzepacz, M.D. as Executive Vice President and Chief Medical Officer
Neurotrope Appoints Paula T. Trzepacz, M.D. as Executive Vice President and Chief Medical Officer
HSMN NewsFeed - 21 Oct 2015
Head Janssen Neuroscientist Appointed to Scientific Advisory Board of Global Dementia Discovery Fund
Head Janssen Neuroscientist Appointed to Scientific Advisory Board of Global Dementia Discovery Fund
HSMN NewsFeed - 24 Mar 2015
StemCells, Inc. Appoints Ian Massey as President and Chief Operating Officer
StemCells, Inc. Appoints Ian Massey as President and Chief Operating Officer
HSMN NewsFeed - 7 Jan 2014
Cortice Biosciences Announces the Appointment of George Farmer, Ph.D. as Chief Executive Officer
Cortice Biosciences Announces the Appointment of George Farmer, Ph.D. as Chief Executive Officer
HSMN NewsFeed - 2 Dec 2013
Forest to Acquire U.S. Marketing Rights to Saphris(R) (asenapine) from Merck
Forest to Acquire U.S. Marketing Rights to Saphris(R) (asenapine) from Merck
HSMN NewsFeed - 10 Sep 2013
Amicus Therapeutics Enters Collaboration With Biogen Idec for Parkinson's Disease
Amicus Therapeutics Enters Collaboration With Biogen Idec for Parkinson's Disease
HSMN NewsFeed - 9 Sep 2013
Keystone Heart's TriGuard(TM) Cerebral Protection Device Receives CE Marking
Keystone Heart's TriGuard(TM) Cerebral Protection Device Receives CE Marking
HSMN NewsFeed - 6 Sep 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
HSMN NewsFeed - 3 Sep 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
HSMN NewsFeed - 14 Aug 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
HSMN NewsFeed - 7 May 2013
Baxter Announces Topline Results of Phase III Study of Immunoglobulin for Alzheimer's Disease
Baxter Announces Topline Results of Phase III Study of Immunoglobulin for Alzheimer's Disease
HSMN NewsFeed - 14 Mar 2012
The Merz Pharma Group Appoints William D. Humphries As New North American Chief Executive Officer
The Merz Pharma Group Appoints William D. Humphries As New North American Chief Executive Officer
HSMN NewsFeed - 16 Aug 2011
NeuroLogica Corporation Receives CE Mark for Its Portable, High-Resolution SPECT Camera, the inSPira HD(TM)
NeuroLogica Corporation Receives CE Mark for Its Portable, High-Resolution SPECT Camera, the inSPira HD(TM)
HSMN NewsFeed - 11 Apr 2011
Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
HSMN NewsFeed - 31 Jan 2011
AVANIR Pharmaceuticals Announces U.S. Launch and Availability of NUEDEXTA for Pseudobulbar Affect
AVANIR Pharmaceuticals Announces U.S. Launch and Availability of NUEDEXTA for Pseudobulbar Affect
HSMN NewsFeed - 14 Jan 2011
GE Healthcare Presents Flutemetamol Data for Detection of Amyloid Plaque Linked to Alzheimer's Disease
GE Healthcare Presents Flutemetamol Data for Detection of Amyloid Plaque Linked to Alzheimer's Disease
HSMN NewsFeed - 13 Jul 2010
Radient Pharmaceuticals Enters Into a Letter of Intent to Acquire Provista Diagnostics Inc.
Radient Pharmaceuticals Enters Into a Letter of Intent to Acquire Provista Diagnostics Inc.
HSMN NewsFeed - 16 Dec 2009
Nanotherapeutics Acquires Two Late Stage Clinical Programs for Alzheimer's Treatment and CDA Disease
Nanotherapeutics Acquires Two Late Stage Clinical Programs for Alzheimer's Treatment and CDA Disease
HSMN NewsFeed - 14 Dec 2009
FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults
FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults
HSMN NewsFeed - 4 Dec 2009
US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
HSMN NewsFeed - 1 Dec 2009
DiaMedica Proposes to Expand Into Neurological and Other Disorders Through Acquisition of Sanomune
DiaMedica Proposes to Expand Into Neurological and Other Disorders Through Acquisition of Sanomune
HSMN NewsFeed - 14 Sep 2009
Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study
Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study
HSMN NewsFeed - 23 Mar 2009
FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression
FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression
HSMN NewsFeed - 23 Feb 2009
AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression
AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression
HSMN NewsFeed - 15 Jan 2009
Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices
Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices
HSMN NewsFeed - 8 Jan 2009
Satori Pharmaceuticals Raises $22M; Names Former Senior Pfizer Executive as CEO
Satori Pharmaceuticals Raises $22M; Names Former Senior Pfizer Executive as CEO
HSMN NewsFeed - 10 Oct 2008
FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
HSMN NewsFeed - 20 Aug 2008
Biovail Appoints Dr. Neil M. Sussman Vice-President, Neurologic & Psychiatric Development
Biovail Appoints Dr. Neil M. Sussman Vice-President, Neurologic & Psychiatric Development
HSMN NewsFeed - 30 Jul 2008
New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation
New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation
HSMN NewsFeed - 30 Jul 2008
Banner Pharmacaps Receives FDA Approval for Valproic Acid Delayed Release Softgel Capsules
Banner Pharmacaps Receives FDA Approval for Valproic Acid Delayed Release Softgel Capsules
HSMN NewsFeed - 9 Jun 2008
Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease
Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease
HSMN NewsFeed - 14 May 2008
FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder
FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder
HSMN NewsFeed - 31 Mar 2008
Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease
Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease
HSMN NewsFeed - 12 Mar 2008
Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
HSMN NewsFeed - 29 Feb 2008
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
HSMN NewsFeed - 21 Jan 2008
Dr. Reddy's Announces Settlement of Exelon(R) (rivastigmine tartrate) ANDA Litigation With Novartis
Dr. Reddy's Announces Settlement of Exelon(R) (rivastigmine tartrate) ANDA Litigation With Novartis
HSMN NewsFeed - 27 Dec 2007
U.S. District Court Decision About Eisai's Legal Action Over Aricept ODT(R) ANDA Filing
U.S. District Court Decision About Eisai's Legal Action Over Aricept ODT(R) ANDA Filing
HSMN NewsFeed - 13 Dec 2007
Forest Laboratories Receives Notification of ANDA Filings for Generic Equivalents of Namenda(R)
Forest Laboratories Receives Notification of ANDA Filings for Generic Equivalents of Namenda(R)
HSMN NewsFeed - 12 Dec 2007
INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia
INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia
HSMN NewsFeed - 16 Nov 2007
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
HSMN NewsFeed - 5 Sep 2007
Eisai Inc. Enters Copromotion Agreement with Salix Pharmaceuticals, Ltd. for Balsalazide Products
Eisai Inc. Enters Copromotion Agreement with Salix Pharmaceuticals, Ltd. for Balsalazide Products
HSMN NewsFeed - 30 Aug 2007
Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
HSMN NewsFeed - 14 Aug 2007
Icagen Announces Alliance with Pfizer in Ion Channel-Focused Therapeutics for Pain and Related Disorders
Icagen Announces Alliance with Pfizer in Ion Channel-Focused Therapeutics for Pain and Related Disorders
HSMN NewsFeed - 24 Jul 2007
Icagen Announces Filing of IND for ICA-105665, a Novel Compound for the Treatment of Epilepsy
Icagen Announces Filing of IND for ICA-105665, a Novel Compound for the Treatment of Epilepsy
HSMN NewsFeed - 24 Jul 2007
Neurochem granted Fast Track designation from U.S. FDA for tramiprosate (ALZHEMED(TM))
Neurochem granted Fast Track designation from U.S. FDA for tramiprosate (ALZHEMED(TM))
HSMN NewsFeed - 3 Jul 2007
Azur Pharma Announces the Acquisition of FazaClo for $42 Million Plus Contingent Milestones
Azur Pharma Announces the Acquisition of FazaClo for $42 Million Plus Contingent Milestones
HSMN NewsFeed - 28 Jun 2007
INVEGA(TM) Receives Marketing Authorization In European Union For Treatment Of Schizophrenia
INVEGA(TM) Receives Marketing Authorization In European Union For Treatment Of Schizophrenia
HSMN NewsFeed - 22 Jun 2007
Tramiprosate (ALZHEMED(TM)) North American Phase III clinical trial progress update
Tramiprosate (ALZHEMED(TM)) North American Phase III clinical trial progress update
HSMN NewsFeed - 18 Jun 2007
NeuroLogica Supports NFL Summit to Review Policies on Concussion and Head Injury
NeuroLogica Supports NFL Summit to Review Policies on Concussion and Head Injury
HSMN NewsFeed - 31 May 2007
AVANIR Receives FDA Approval for New Formulation of Currently Marketed Antipsychotic Drug FazaClo
AVANIR Receives FDA Approval for New Formulation of Currently Marketed Antipsychotic Drug FazaClo
HSMN NewsFeed - 11 May 2007
Barr Receives Tentative Approval for a Generic Version of Razadyne(R) Tablets, 4mg, 8mg and 12mg
Barr Receives Tentative Approval for a Generic Version of Razadyne(R) Tablets, 4mg, 8mg and 12mg
HSMN NewsFeed - 30 Apr 2007
Duramed's ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) Tablets Receives Two New FDA Approvals
Duramed's ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) Tablets Receives Two New FDA Approvals
HSMN NewsFeed - 27 Apr 2007
FDA Approves INVEGA (TM) for Long-Term Maintenance Treatment of Schizophrenia
FDA Approves INVEGA (TM) for Long-Term Maintenance Treatment of Schizophrenia
HSMN NewsFeed - 18 Apr 2007
Wyeth Responds to Special Report Published in New England Journal of Medicine
Wyeth Responds to Special Report Published in New England Journal of Medicine
HSMN NewsFeed - 13 Apr 2007
FDA Approves New Dose of RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment
FDA Approves New Dose of RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment
HSMN NewsFeed - 30 Mar 2007
Study Suggests INVEGA(TM) Helps Patients With Schizophrenia Maintain Symptom Control
Study Suggests INVEGA(TM) Helps Patients With Schizophrenia Maintain Symptom Control
HSMN NewsFeed - 20 Mar 2007
Myriad Genetics Completes Enrollment in Second Phase 3 Clinical Trial of Flurizan(TM) in Alzheimer's Disease
Myriad Genetics Completes Enrollment in Second Phase 3 Clinical Trial of Flurizan(TM) in Alzheimer's Disease
HSMN NewsFeed - 19 Mar 2007
Avid Announces Results of AV-1 Molecular Imaging Agent for Alzheimer's Disease Presented at AD/PD Meeting
Avid Announces Results of AV-1 Molecular Imaging Agent for Alzheimer's Disease Presented at AD/PD Meeting
HSMN NewsFeed - 15 Mar 2007
Alexian Brothers Hospital Network To Bring Advanced Brain Mapping Technology To Chicagoland
Alexian Brothers Hospital Network To Bring Advanced Brain Mapping Technology To Chicagoland
HSMN NewsFeed - 5 Feb 2007
Amarin Announces Completion of Two Phase III Trials With Miraxion in Huntington's Disease
Amarin Announces Completion of Two Phase III Trials With Miraxion in Huntington's Disease
HSMN NewsFeed - 30 Jan 2007
AVANIR Receives FDA Approvable Letter for New Formulation of Currently Marketed Antipsychotic Drug FazaClo
AVANIR Receives FDA Approvable Letter for New Formulation of Currently Marketed Antipsychotic Drug FazaClo
HSMN NewsFeed - 19 Jan 2007
Bayer Schering Pharma to Develop New Imaging Compounds for Detection of Neurodegenerative Diseases
Bayer Schering Pharma to Develop New Imaging Compounds for Detection of Neurodegenerative Diseases
HSMN NewsFeed - 11 Jan 2007
Bio-Rad and Axis-Shield PLC Sign Agreement for Anti-CCP Test for Early Detection of Rheumatoid Arthritis
Bio-Rad and Axis-Shield PLC Sign Agreement for Anti-CCP Test for Early Detection of Rheumatoid Arthritis
HSMN NewsFeed - 4 Jan 2007
Eli Lilly and Company Statement Regarding Today's New York Times Article - January 4, 2007
Eli Lilly and Company Statement Regarding Today's New York Times Article - January 4, 2007
HSMN NewsFeed - 4 Jan 2007
Lilly and Plaintiffs' Attorneys Enter Into Agreements to Settle Zyprexa(R) Product Liability Litigation
Lilly and Plaintiffs' Attorneys Enter Into Agreements to Settle Zyprexa(R) Product Liability Litigation
HSMN NewsFeed - 20 Dec 2006
Alkermes Announces Submission of New Drug Application for RISPERDAL(R) CONSTA(R) in Japan
Alkermes Announces Submission of New Drug Application for RISPERDAL(R) CONSTA(R) in Japan
HSMN NewsFeed - 1 Dec 2006
Lilly Responds to the Cost-Effectiveness Analysis of the CATIE Schizophrenia Trial
Lilly Responds to the Cost-Effectiveness Analysis of the CATIE Schizophrenia Trial
HSMN NewsFeed - 9 Nov 2006
Neurobiological Technologies, Inc. Comments on Recent Stroke Trial Developments
Neurobiological Technologies, Inc. Comments on Recent Stroke Trial Developments
HSMN NewsFeed - 8 Nov 2006
BioSante Pharmaceuticals Signs Bio-E-Gel(R) Marketing Agreement With Bradley Pharmaceuticals, Inc.
BioSante Pharmaceuticals Signs Bio-E-Gel(R) Marketing Agreement With Bradley Pharmaceuticals, Inc.
HSMN NewsFeed - 2 Nov 2006
Tramiprosate (ALZHEMED(TM)) Phase II Clinical Results Published in Neurology
Tramiprosate (ALZHEMED(TM)) Phase II Clinical Results Published in Neurology
HSMN NewsFeed - 19 Oct 2006
PharmaNova Grants Exclusive U.S. License to Depomed for Extended Release Gabapentin Use in Hot Flashes
PharmaNova Grants Exclusive U.S. License to Depomed for Extended Release Gabapentin Use in Hot Flashes
HSMN NewsFeed - 13 Oct 2006
U.S. Food and Drug Administration Approves ARICEPT(R) for Treatment of Severe Alzheimer's Disease
U.S. Food and Drug Administration Approves ARICEPT(R) for Treatment of Severe Alzheimer's Disease
HSMN NewsFeed - 12 Oct 2006
BioSante Pharmaceuticals Presents Bio-E-Gel(R) Woman-to-Partner Transfer Study at Menopause Society Meeting
BioSante Pharmaceuticals Presents Bio-E-Gel(R) Woman-to-Partner Transfer Study at Menopause Society Meeting
HSMN NewsFeed - 11 Oct 2006
Osta Announces Promising Clinical Results on Blood Tests for Parkinson's Disease & Alzheimer's Disease
Osta Announces Promising Clinical Results on Blood Tests for Parkinson's Disease & Alzheimer's Disease
HSMN NewsFeed - 6 Oct 2006
FDA Approves RISPERDAL(R) for Treatment of Irritability Associated with Autistic Disorder
FDA Approves RISPERDAL(R) for Treatment of Irritability Associated with Autistic Disorder
HSMN NewsFeed - 12 Sep 2006
Icagen Reports Results of Data Monitoring Committee Meeting in Phase III Assert Trial of ICA-17043
Icagen Reports Results of Data Monitoring Committee Meeting in Phase III Assert Trial of ICA-17043
HSMN NewsFeed - 18 Jul 2006
AstraZeneca Submits NDA for Sustained Release Formulation of SEROQUEL(R) for Schizophrenia Treatment
AstraZeneca Submits NDA for Sustained Release Formulation of SEROQUEL(R) for Schizophrenia Treatment
HSMN NewsFeed - 23 May 2006
New Study Suggests Symbyax(R) Significantly Improves Symptoms of Treatment-Resistant Depression
New Study Suggests Symbyax(R) Significantly Improves Symptoms of Treatment-Resistant Depression
HSMN NewsFeed - 23 May 2006
AVANIR Announces the Intended Acquisition of a Private Specialty Pharmaceutical Company
AVANIR Announces the Intended Acquisition of a Private Specialty Pharmaceutical Company
HSMN NewsFeed - 22 May 2006
New Studies Examine SEROQUEL(R) in Combination With Antidepressant Therapy in Patients With Depression
New Studies Examine SEROQUEL(R) in Combination With Antidepressant Therapy in Patients With Depression
HSMN NewsFeed - 19 May 2006
Targacept Announces Positive Phase II Results for TC-1734 (AZD3480) in Memory Impaired Older Subjects
Targacept Announces Positive Phase II Results for TC-1734 (AZD3480) in Memory Impaired Older Subjects
Additional items found! 168

Members Archive contains
168 additional stories matching:
dementia
(Password required)
dementia
(Password required)